Form D · Biotechnology
AVM BIOTECHNOLOGY, LLC
Seattle, WA · CIK 0001463741
Offering snapshot reported May 3, 2021 · SEC filing
- Reported sold
- $4.43M Offering amount: $14.7M
- Investors reported
- 22 Form D · investor count
- Minimum accepted
- $25K Reported outside-investor minimum
- First sale
- Apr 16, 2021 As reported in this filing
Fundraising history
Reported soldDates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.
What changed?
Latest filing versus its linked predecessor, where available.
- Reported sold$2,570,215 → $4,428,241
- Reported investors14 → 22
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 3, 2021 | Amendment | $4,428,241 | $1,858,026vs Feb 24, 2020 | 22 | SEC filing |
| Feb 24, 2020 | Initial | $2,570,215 | No comparison | 14 | SEC filing |
| May 9, 2019 | Initial | $1,395,213 | No comparison | 13 | SEC filing |
| Dec 12, 2017 | Amendment | $5,515,000 | $5,475,000vs Feb 24, 2016 | 25 | SEC filing |
| Nov 21, 2017 | Amendment | $3,715,000 | $650,000vs Dec 13, 2016 | 15 | SEC filing |
| Mar 30, 2017 | Amendment | $3,265,000 | $200,000vs Dec 13, 2016 | 13 | SEC filing |
| Dec 13, 2016 | Amendment | $3,065,000 | $225,000vs Aug 10, 2016 | 11 | SEC filing |
| Aug 10, 2016 | Amendment | $2,840,000 | $100,000vs Jun 9, 2016 | 9 | SEC filing |
| Jun 9, 2016 | Amendment | $2,740,000 | $100,000vs May 13, 2016 | 8 | SEC filing |
| May 13, 2016 | Amendment | $2,640,000 | $50,000vs Apr 29, 2016 | 7 | SEC filing |
| Apr 29, 2016 | Amendment | $2,590,000 | $2,200,000vs Mar 16, 2016 | 6 | SEC filing |
| Mar 16, 2016 | Amendment | $390,000 | $350,000vs Feb 24, 2016 | 3 | SEC filing |
| Feb 24, 2016 | Initial | $40,000 | No comparison | 1 | SEC filing |
| Apr 22, 2014 | Initial | $1,500,000 | No comparison | 1 | SEC filing |
| Jun 3, 2013 | Amendment | $708,000 | $408,000vs Nov 25, 2011 | 12 | SEC filing |
| Nov 25, 2011 | Amendment | $300,000 | $200,000vs Aug 3, 2011 | 4 | SEC filing |
| Aug 3, 2011 | Initial | $100,000 | No comparison | 1 | SEC filing |
| Sep 8, 2009 | Amendment | $225,000 | $50,000vs May 11, 2009 | 4 | SEC filing |
| May 11, 2009 | Initial | $175,000 | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $35K
- Finders' fees
- $0
- Form D file number
- 021-361171
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Weild & Co | 132398 | Todd Colin Bertsch · CRD 2449486 |
Source: Form D, filed May 3, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Theresa Deisher | Director, Executive |
| Adam John Fountain | Promoter |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1749 Dexter Ave N
Seattle, WA, 98109
Seattle, WA, 98109